Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior

Hippocampus

Volumn 20, Issue 8, 2010, Pages 911-916

  Goeldner, Celia ^a,b,c,d,e   Reiss, David ^b,c,d   Kieffer, Brigitte L ^b,c,d   Ouagazzal, Abdel Mouttalib ^b,c,d  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c INSERM   (France)

^d CNRS   (France)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Anxiety; Despair behavior; Mice; Nociceptin orphanin FQ peptide; NOP receptor

Indexed keywords

FLUOXETINE; NOCICEPTIN; NOCICEPTIN RECEPTOR ANTAGONIST; UFP 101; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DARKNESS; DISSOCIATION; EMOTION; FORCED SWIMMING TEST; HIPPOCAMPUS; HOPELESSNESS; LIGHT; MALE; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DARK ADAPTATION; DEPRESSION; DISEASE MODELS, ANIMAL; HINDLIMB SUSPENSION; HIPPOCAMPUS; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; OPIOID PEPTIDES; SPIRO COMPOUNDS; SWIMMING;

EID: 77954937874     PISSN: 10509631     EISSN: 10981063     Source Type: Journal    
DOI: 10.1002/hipo.20760     Document Type: Article

References (37)

1. Bongsebandhu-phubhakdi S, Manabe T. 2007. The neuropeptide nociceptin is a synaptically released endogenous inhibitor of hippocampal long-term potentiation. J Neurosci 27:4850-4858. (Pubitemid 46699051)
2. Calo' G, Guerrini R, Rizzi A, Salvadori S, Burmeister M, Kapusta DR, Lambert DG, Regoli D. 2005. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev 11:97-112. (Pubitemid 41278976)
3. Campbell S, Macqueen G. 2004. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 29:417-426. (Pubitemid 40075713)
4. Cryan JF, Mombereau C, Vassout A. 2005a. The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571-625. (Pubitemid 40755457)
5. Cryan JF, Valentino RJ, Lucki I. 2005b. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29:547-569. (Pubitemid 40755456)
6. Darland T, Heinricher MM, Grandy DK. 1998. Orphanin FQ/nociceptin: A role in pain and analgesia, but so much more. Trends Neurosci 21:215-221. (Pubitemid 28191816)
7. Engin E, Treit D. 2008. The effects of intra-cerebral drug infusions on animals' unconditioned fear reactions: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry 32:1399-1419. (Pubitemid 352033664)
8. Gavioli EC, Calo' G. 2006. Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn Schmiedebergs Arch Pharmacol 372:319-330.
9. Gavioli EC, Rizzi A, Marzola G, Zucchini S, Regoli D, Calo' G. 2007. Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice. Peptides 28:1229-1239. (Pubitemid 46843392)
10. Goeldner C, Reiss D, Wichmann J, Meziane H, Kieffer BL, Ouagazzal AM. 2008. Nociceptin receptor impairs recognition memory via interaction with NMDA receptor-dependent mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in the hippocampus. J Neurosci 28:2190-2198.
11. Goeldner C, Reiss D, Wichmann J, Kieffer BL, Ouagazzal AM. 2009. Activation of nociceptin opioid peptide (NOP) receptor impairs contextual fear learning in mice through glutamatergic mechanisms. Neurobiol Learn Mem 91:393-401.
12. Gonzalez LE, Ouagazzal AM, File SE. 1998. Stimulation of benzodiazepine receptors in the dorsal hippocampus and median raphé reveals differential GABAergic control in two animal tests of anxiety. Eur J Neurosci 10:3673-3680.
13. Gu H, Hu D, Hong XR, Mao J, Cui Y, Hui N, Sha JY. 2003. Changes and significance of orphanin and serotonin in patients with postpartum depression. Zhonghua Fu Chan Ke Za Zhi 38:727-728.
14. Hirao A, Imai A, Sugie Y, Yamada Y, Hayashi S, Toide K. 2008. Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]- 2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent. J Pharmacol Sci 106:361-368.
15. Jenck F, Ouagazzal A, Pauly-Evers M, Moreau JL. 2000. OrphaninFQ: Role in behavioral fear responses and vulnerability to stress? Mol Psychiatry 5:572-574.
16. Köster A, Montkowski A, Schulz S, Stübe EM, Knaudt K, Jenck F, Moreau JL, Nothacker HP, Civelli O, Reinscheid RK. 1999. Targeted disruption of orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci 96:10444-10449.
17. Lambert DG. 2008. The nociceptin/orphanin FQ receptor: A target with broad therapeutic potential. Nat Rev Drug Discov 7:694-710.
18. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK. 2008. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methy-lisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352.
19. Mamiya T, Yamada K, Miyamoto Y, Konig N, Watanabe Y, Noda Y, Nabeshima T. 2003. Neuronal mechanism of nociceptin-induced modulation of learning and memory: Involvement of N-methyl-D-aspartate receptors. Mol Psychiatry 8:752-765. (Pubitemid 36976433)
20. Meziane H, Ouagazzal AM, Aubert L, Wietrzych M, Krezel W. 2006. Estrous cycle effects on behavior of C57BL/6J and BALB/cByJ female mice: Implications for phenotyping strategies. Genes Brain Behav 6:192-200. (Pubitemid 46328591)
21. Ouagazzal AM, Moreau JL, Pauly-Evers M, Jenck F. 2003. Impact of environmental housing conditions on the emotional responses of mice deficient for nociceptin/orphanin FQ peptide precursor gene. Behav Brain Res 144:111-117. (Pubitemid 37011172)
22. Paxinos G, Franklin KBJ. 2001. The Mouse Brain in Stereotaxic Coordinates,2nd ed. San Diego: Academic.
23. Płaźnik A, Kostowski W. 1985. Modification of behavioral response to intra-hippocampal injections of noradrenaline and adrenoceptor agonists by chronic treatment with desipramine and citalopram: Functional aspects of adaptive receptor changes. Eur J Pharmacol 101:305-306.
24. Przegaliński E, Tatarczyńska E, Dereń-Wesołek A, Chojnacka-Wojcik E. 1997. Antidepressant-like effects of a partial agonist at strychnine- insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 36:31-37. (Pubitemid 27115840)
25. Redrobe JP, Calo' G, Regoli D, Quirion R. 2002. Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn Schmiedeberg's Arch Pharmacol 365:164-167. (Pubitemid 34253110)
26. Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, Trapella C, Regoli D, Calò G. 2007. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7- [[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H- benzocyclohepten-5-ol]: In vivo studies. J Pharmacol Exp Ther 321:968-974. (Pubitemid 46762707)
27. Rodi D, Zucchini S, Simonato M, Cifani C, Massi M, Polidori C. 2008. Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: Evidence for involvement of the bed nucleus of the stria terminalis. Psychopharmacology 196:523-531.
28. Roozendaal B, Lengvilas R, McGaugh JL, Civelli O, Reinscheid RK. 2007. Orphanin FQ/nociceptin interacts with the basolateral amygdala noradrenergic system in memory consolidation. Learn Mem 14:29-35. (Pubitemid 46203564)
29. Sandin J, Ogren SO, Terenius L. 2004. Nociceptin/orphanin FQ modulates spatial learning via ORL-1 receptors in the dorsal hippocampus of the rat. Brain Res 997:222-233. (Pubitemid 38058527)
30. Schlicker E, Morari M. 2000. Nociceptin/orpahin FQ, neurotransmitter release in the central nervous system. Peptides 21:1023-1029.
31. Uchiyama H, Yamaguchi T, Toda A, Hiranita T, Watanabe S, Eyanagi R. 2008. Involvement of the GABA/benzodiazepine receptor in the anxiolytic-like effect of nociceptin/orphanin FQ. Eur J Pharmacol 590:185-189.
32. Varty GB, Lu SX, Morgan CA, Cohen-Williams ME, Hodgson RA, Smith-Torhan A, Zhang H, Fawzi AB, Graziano MP, Ho GD, Matasi J, Tulshian D, Coffin VL, Carey GJ. 2008. The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2. 1] octan-3-ol (SCH 221510). J Pharmacol Exp Ther 326:672-682.
33. Vitale G, Ruggieri V, Filaferro M, Frigeri C, Alboni S, Tascedda F, Brunello N, Guerrini R, Cifani C, Massi M. 2009. Chronic treatment with the selective NOP receptor antagonist [Nphe(1),Arg (14),Lys (15)]N/OFQ-NH (2) (UFP-101) reverses the behavioral and biochemical effects of unpredictable chronic mild stress in rats. Psychopharmacology 207:173-189.
34. Wang LN, Liu LF, Zhang JX, Zhao GF. 2009. Plasma levels of nociceptin/ orphanin FQ in patients with bipolar disorders and health adults. Zhonghua Yi Xue Za Zhi 89:916-918.
35. Wei WZ, Xie CW. 1999. Orphanin FQ suppresses NMDA receptor-dependent long-term depression and depotentiation in hippocampal dentate gyrus. Learn Mem 6:467-477.
36. Yu TP, Xie CW. 1998. Orphanin FQ/nociceptin inhibits synaptic transmission and long-term potentiation in rat dentate gyrus through postsynaptic mechanisms. J Neurophysiol 80:1277-1284.
37. Zhang HT, Frith SA, Wilkins J, O'Donnell JM. 2001. Comparison of the effects of isoproterenol administered into the hippocampus, frontal cortex, or amygdala on behavior of rats maintained by differential reinforcement of low response rate. Psychopharmacology 159:89-97.